{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T12:33:48Z","timestamp":1784291628638,"version":"3.55.0"},"reference-count":14,"publisher":"BMJ","issue":"e3","license":[{"start":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T00:00:00Z","timestamp":1687305600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Fondazione Regionale Ricerca Biomedica Regione Lombardia","award":["CP 12\/2018"],"award-info":[{"award-number":["CP 12\/2018"]}]},{"DOI":"10.13039\/501100013122","name":"Fondazione Oncologia Niguarda Onlus","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013122","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Support Palliat Care"],"accepted":{"date-parts":[[2023,5,17]]},"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>Early-onset colorectal cancer (EO-CRC) incidence is increasing, raising a clinical challenge. Clinicians tend to treat EO-CRC patients with more intensive regimens despite the lack of survival benefits, based on an age-related bias. Limited evidence is available regarding treatment-related toxicities in this peculiar subset of patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We performed a literature search in MEDLINE\/PubMed, EMBASE and Scopus, looking for reporting of nausea, vomiting and diarrhoea occurring in patients with EO-CRC, defined by age lower than 50 years old at initial diagnosis, while receiving anticancer treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>2318 records were screened and 9 full-text articles were considered eligible for inclusion for a total of 59\u2009783 patients (of whom 8681 EO-CRC patients). We found nausea and vomiting occurring at higher incidence among EO-CRC compared with older patients, while no difference was reported as for diarrhoea. Peritoneal involvement, age younger than 40, female gender, suboptimal adherence to guidelines and oxaliplatin might represent potential risk factors for increased nausea and vomiting in patients with EO-CRC.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>EO-CRC patients experience more nausea and vomiting but equal or less diarrhoea compared with older patients. Adherence to clinical guidelines is recommended, and more data are warranted to assess if an enhanced antiemetic approach might be required, particularly in case of specific risk factors.<\/jats:p><\/jats:sec>","DOI":"10.1136\/spcare-2023-004203","type":"journal-article","created":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T18:20:43Z","timestamp":1687371643000},"page":"e885-e889","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Young-onset colorectal cancer: treatment-related nausea, vomiting and diarrhoea"],"prefix":"10.1136","volume":"13","clinical-trial-number":[{"clinical-trial-number":"nct00272051","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00364013","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Gianluca","family":"Mauri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martino","family":"Pedrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Ghezzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katia","family":"Bencardino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Mariano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Bonazzina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Serra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Pedrazzoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9379-3569","authenticated-orcid":false,"given":"Riccardo","family":"Caccialanza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia Martina","family":"Cavestro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Siena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Artale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0780-0409","authenticated-orcid":false,"given":"Andrea","family":"Sartore-Bianchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,6,21]]},"reference":[{"key":"2024121022580593000_13.e3.e885.1","doi-asserted-by":"publisher","DOI":"10.1002\/1878-0261.12417"},{"key":"2024121022580593000_13.e3.e885.2","doi-asserted-by":"crossref","first-page":"e1846","DOI":"10.1200\/OP.20.01010","article-title":"Care patterns and overall survival in patients with early-onset metastatic colorectal cancer","volume":"17","author":"Kanter","year":"2021","journal-title":"JCO Oncol Pract"},{"key":"2024121022580593000_13.e3.e885.3","doi-asserted-by":"crossref","first-page":"4009","DOI":"10.1200\/JCO.21.02008","article-title":"Early-onset colorectal adenocarcinoma in the IDEA database: treatment adherence, toxicities, and outcomes with 3 and 6 months of adjuvant Fluoropyrimidine and Oxaliplatin","volume":"39","author":"Fontana","year":"2021","journal-title":"JCO"},{"key":"2024121022580593000_13.e3.e885.4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.33.5281"},{"key":"2024121022580593000_13.e3.e885.5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.41.1975"},{"key":"2024121022580593000_13.e3.e885.6","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1002\/cncr.28297","article-title":"Symptom burden among young adults with breast or colorectal cancer: symptom burden in young adult oncology","volume":"120","author":"Sanford","year":"2014","journal-title":"Cancer"},{"key":"2024121022580593000_13.e3.e885.7","doi-asserted-by":"crossref","first-page":"6527","DOI":"10.21873\/anticanres.11254","article-title":"Control of nausea and vomiting in patients with colorectal cancer receiving chemotherapy with moderate Emetic risk","volume":"36","author":"Suzuki","year":"2016","journal-title":"AR"},{"key":"2024121022580593000_13.e3.e885.8","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-016-2676-4","article-title":"Young patients and gastrointestinal (GI) tract malignancies - are we addressing the unmet needs","volume":"16","author":"Perl","year":"2016","journal-title":"BMC Cancer"},{"key":"2024121022580593000_13.e3.e885.9","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ejca.2022.02.031","article-title":"FOLFOXIRI and Bevacizumab in patients with early-onset metastatic colorectal cancer. A pooled analysis of TRIBE and Tribe2 studies","volume":"167","author":"Antoniotti","year":"2022","journal-title":"European Journal of Cancer"},{"key":"2024121022580593000_13.e3.e885.10","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1002\/ijc.34156","article-title":"Early onset metastatic colorectal cancer in patients receiving Panitumumab-based Upfront strategy: overall and sex-specific outcomes in the Valentino trial","volume":"151","author":"Raimondi","year":"2022","journal-title":"Int J Cancer"},{"key":"2024121022580593000_13.e3.e885.11","doi-asserted-by":"crossref","unstructured":"Meng L , Thapa R , Delgado MG , et al . Age-related disparity of survival outcomes and treatment-related adverse events in patients with metastatic colorectal cancer. Oncology [Preprint] 2022. doi:10.1101\/2022.10.08.22280865","DOI":"10.1101\/2022.10.08.22280865"},{"key":"2024121022580593000_13.e3.e885.12","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw270"},{"key":"2024121022580593000_13.e3.e885.13","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1007\/s00384-020-03731-7","article-title":"Risk factors of chemotherapy-induced nausea and vomiting in patients with metastatic colorectal cancer: a prospective cohort study (Ycog1301)","volume":"35","author":"Takei","year":"2020","journal-title":"Int J Colorectal Dis"},{"key":"2024121022580593000_13.e3.e885.14","doi-asserted-by":"crossref","first-page":"4761","DOI":"10.1007\/s00520-020-05310-6","article-title":"Guideline concordant care for prevention of acute chemotherapy-induced nausea and vomiting in children, adolescents, and young adults","volume":"28","author":"Beauchemin","year":"2020","journal-title":"Support Care Cancer"}],"container-title":["BMJ Supportive &amp; Palliative Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/spcare-2023-004203","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T07:15:48Z","timestamp":1733901348000},"score":1,"resource":{"primary":{"URL":"https:\/\/spcare.bmj.com\/lookup\/doi\/10.1136\/spcare-2023-004203"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,21]]},"references-count":14,"journal-issue":{"issue":"e3","published-online":{"date-parts":[[2024,1,8]]},"published-print":{"date-parts":[[2023,12]]}},"alternative-id":["10.1136\/spcare-2023-004203"],"URL":"https:\/\/doi.org\/10.1136\/spcare-2023-004203","relation":{},"ISSN":["2045-435X","2045-4368"],"issn-type":[{"value":"2045-435X","type":"print"},{"value":"2045-4368","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,21]]}}}